Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This phase III trial is studying how well giving carboplatin and vincristine together with standard local ophthalmic therapy works in treating children with intraocular retinoblastoma. Drugs used in chemotherapy, such as carboplatin and vincristine, work in different ways to stop tumor tumor from dividing so they stop growing or die. It is not yet known whether neoadjuvant chemotherapy combined with standard local ophthalmic therapy is effective in treating intraocular retinoblastoma.
| Condition | Intervention | Phase |
|---|---|---|
|
Intraocular Retinoblastoma |
Procedure: cryosurgery Procedure: infrared laser therapy Radiation: iodine I 125 Radiation: ruthenium Ru 106 Drug: carboplatin Drug: vincristine sulfate Radiation: radiation therapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma |
- Event-free Survival [ Time Frame: At 2 years ] [ Designated as safety issue: No ]An event is defined as the need for non-protocol therapy, defined as additional on-protocol chemotherapy, enucleation or external beam radiation, among patients with Group B intraocular tumors with a schedule of neoadjuvant 2-agent (Vincristine/Carboplatin) chemotherapy (chemo-reduction) and standardized local ophthalmic therapy.
- Use of Nonprotocol Chemotherapy [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]Use of nonprotocol chemotherapy at the patient level and enucleation and EBRT will be descriptively summarized at the patient and eye levels.
- Response Rate (RR) at Patient and Eye Levels After the First Course [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]RR will be estimated. The response after 1 course of chemotherapy will be used to better define response to this neoadjuvant systemic chemotherapy, prior to the use of local ophthalmic therapy. Response to subsequent courses will help define response to combined systemic chemotherapy and local ophthalmic therapy.
- Event-free Survival Rate (EFSR) Defined as the Need for Non-protocol Chemotherapy, Enucleation, or EBRT at the Patient Level [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]EFSR will be estimated for patients who respond to vincristine and carboplatin after an initial 1 cycle of chemoreduction
- Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 [ Time Frame: From the beginning of treatment, assessed up to 10 years ] [ Designated as safety issue: Yes ]
| Enrollment: | 28 |
| Study Start Date: | December 2005 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Vincristine Sulfate and Carboplatin and surgery
Patients receive chemoreduction comprising carboplatin IV (Pts < 36 months: 18.6 mg/kg Pts ≥ 36 months: 560 mg/m2) over 60 minutes followed by vincristine sulfate IV (Pts < 36 months: 0.05 mg/kg Pts ≥36 months: 1.5 mg/m2) over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local infrared laser therapy, cryosurgery, and/or radiation therapy (radioactive) plaque comprising iodine I 125 or ruthenium Ru 106.
|
Procedure: cryosurgery
Application of extreme cold to destroy abnormal or diseased tissue.
Other Names:
Procedure: infrared laser therapy
Laser therapy or "photobiomodulation" is the use of specific wavelength of light (red and near-infrared) to create therapeutic effects
Radiation: iodine I 125
Undergo radioactive therapy
Other Names:
Radiation: ruthenium Ru 106
Undergo radioactive therapy
Other Names:
Drug: carboplatin
Given IV
Other Names:
Drug: vincristine sulfate
Given IV
Other Names:
Radiation: radiation therapy
Undergo radioactive therapy
Other Names:
|
Detailed Description:
PRIMARY OBJECTIVES:
I. Determine the 2-year event-free survival of patients with Group B intraocular retinoblastoma treated with neoadjuvant chemoreduction comprising carboplatin and vincristine and standardized local ophthalmic therapy.
SECONDARY OBJECTIVES:
I. Determine the response rate after one course of chemoreduction (before standardized local ophthalmic therapy) in these patients.
II. Correlate response rate with event-free survival in patients treated with this regimen.
III. Determine the incidence of toxic effects in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive chemoreduction comprising carboplatin IV over 60 minutes followed by vincristine IV over 1-2 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the first course of chemoreduction, patients undergo standardized local ophthalmic therapy comprising local laser therapy, cryotherapy, and/or radioactive plaque comprising iodine I 125 or ruthenium Ru 106.
Patients are followed every 3-4 weeks until there is no active tumor seen on a minimum of 3 ophthalmic exams under anesthesia, every 6-8 weeks until 3 years of age, every 4-6 months until 10 years of age, and then annually thereafter.
Eligibility| Ages Eligible for Study: | up to 5 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Newly diagnosed Group B intraocular retinoblastoma meeting 1 of the following criteria:
- Group B tumor(s) in 1 eye
- Group B tumor(s) in both eyes
- Group A tumor in 1 eye and Group B tumor(s) in the other eye
- Group E tumor in 1 eye that has been enucleated and Group B tumor(s) in the remaining eye at the time of enucleation of the Group E tumor
-
Defined by the International Classification System for Intraocular Retinoblastoma as follows:
-
Group A: Small tumors (≤ 3 mm in greatest dimension) confined to the retina, away from foveola and disc meeting the following criteria:
- More than 3 mm from fovea
- More than 1.5 mm from optic disk
-
Group B: Tumors more than 3 mm meeting the following criteria:
- Confined to the retina in any location not in Group A
- Tumor associated subretinal fluid < 3 mm from the tumor margin with no subretinal seeding
-
Group E: Must have ≥ 1 of the following present:
- Tumor touching the lens
- Tumor anterior to anterior vitreous face involving ciliary body or anterior segment
- Diffuse infiltrating retinoblastoma
- Neovascular glaucoma
- Opaque media from hemorrhage
- Tumor necrosis with aseptic orbital cellulites
- Phthisis bulbi
-
- Confirmation of diagnosis by CT scan or MRI of the brain and orbits AND an ophthalmologic evaluation under anesthesia within the past 3 weeks
- No choroidal and/or optic nerve invasion past the lamina cribosa
- No evidence of extraocular retinoblastoma clinically or by head and orbital MRI and/or CT scan
- No tumor present on histological exam at the cut end of the optic nerve for any Group E eye enucleated before study entry
- Performance status - ECOG 0-2
- Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
- AST or ALT < 2.5 times ULN for age
- Creatinine clearance (based on Schwartz formula) or radioisotope glomerular filtration rate ≥ 70mL/min/1.73 m^2
- No prior chemotherapy
- No other concurrent chemotherapy
- No prior radiotherapy
- No other concurrent radiotherapy, including intensity-modulated stereotactic, or proton beam radiotherapy
- Prior enucleation of one eye allowed provided the remaining eye is Group B
- No concurrent enucleation
- No prior local ophthalmic therapy for retinoblastoma
- No other prior therapy for retinoblastoma
- No local therapy during chemotherapy course 1
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00079417
| United States, California | |
| Children's Oncology Group | |
| Arcadia, California, United States, 91006-3776 | |
| United States, Washington | |
| Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | |
| Seattle, Washington, United States, 98109 | |
| Principal Investigator: | Debra Friedman | Children's Oncology Group |
More Information
No publications provided
| Responsible Party: | Children's Oncology Group |
| ClinicalTrials.gov Identifier: | NCT00079417 History of Changes |
| Other Study ID Numbers: | ARET0331, NCI-2009-00422, CDR0000355721, COG-ARET0331, U10CA098543 |
| Study First Received: | March 8, 2004 |
| Results First Received: | December 23, 2013 |
| Last Updated: | December 23, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Retinoblastoma Eye Diseases Eye Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors Retinal Diseases |
Retinal Neoplasms Carboplatin Vincristine Antimitotic Agents Antineoplastic Agents Antineoplastic Agents, Phytogenic Mitosis Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Therapeutic Uses Tubulin Modulators |
ClinicalTrials.gov processed this record on March 03, 2015